← Leaderboards
Chu Chen
Louisiana State Univ Hsc New Orleans
$13,333,735
Attributed
$13,333,735
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4.4M · FY2007–23$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$13,333,735 · 9
By mechanism
R01$8,424,167 · 4
RF1$4,430,155 · 2
R21$337,413 · 1
R03$142,000 · 1
P20$0 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposSynapsesEndocannabinoids2-ArachidonylglycerolS DiseasePreventNeurodegenerative DisordersImpaired CognitionMediatingNerve DegenerationMolecularNeuronsSynaptic FunctionProductionCognitive FunctionMemorySignal TransductionEnzymesMonoacylglycerol LipasesBrainHippocampus (Brain)AnimalsNeuroinflammationNeuropathology
Grant awards (36)
Silencing of astrocytic MAGL as a therapy for Alzheimerâs disease$2,278,287
RF1 · FY2023 · AG · contact PI
Endocannabinoids in neurodegenerative diseases$2,151,868
RF1 · FY2023 · NS · contact PI
Endocannabinoids in Neurodegenerative Diseases$387,500
R01 · FY2022 · NS · contact PI
Traumatic brain injury and Alzheimer's disease$387,500
R01 · FY2022 · AG · contact PI
Endocannabinoid Metabolism and Synaptic Function$387,500
R01 · FY2022 · MH · contact PI
Endocannabinoids in Neurodegenerative Diseases$386,665
R01 · FY2021 · NS · contact PI
Traumatic brain injury and Alzheimer's disease$386,250
R01 · FY2021 · AG · contact PI
Endocannabinoid Metabolism and Synaptic Function$385,625
R01 · FY2021 · MH · contact PI
Endocannabinoid Metabolism and Synaptic Function$385,000
R01 · FY2020 · MH · contact PI
Traumatic brain injury and Alzheimer's disease$385,000
R01 · FY2020 · AG · contact PI
Endocannabinoids in Neurodegenerative Diseases$385,000
R01 · FY2020 · NS · contact PI
Traumatic brain injury and Alzheimer's disease$383,125
R01 · FY2019 · AG · contact PI
Endocannabinoids in Neurodegenerative Diseases$381,250
R01 · FY2019 · NS · contact PI
Endocannabinoid Metabolism and Synaptic Function$328,403
R01 · FY2019 · MH · contact PI
Endocannabinoid Metabolism and Synaptic Function$54,673
R01 · FY2019 · MH · contact PI
Endocannabinoids in Neurodegenerative Diseases$367,500
R01 · FY2018 · NS · contact PI
Traumatic brain injury and Alzheimer's disease$367,291
R01 · FY2018 · AG · contact PI
Endocannabinoid Metabolism and Synaptic Function$365,000
R01 · FY2018 · MH · contact PI
Endocannabinoids in Neurodegenerative Diseases$315,000
R01 · FY2016 · NS · contact PI
Endocannabinoids in Neurodegenerative Diseases$9,680
R01 · FY2016 · NS · contact PI
Endocannabinoids in Neurodegenerative Diseases$315,000
R01 · FY2015 · NS · contact PI
Endocannabinoids in Neurodegenerative Diseases$311,851
R01 · FY2014 · NS · contact PI
Endocannabinoids in Neurodegenerative Diseases$303,975
R01 · FY2013 · NS · contact PI
Endocannabinoids in Neurodegenerative Diseases$49,726
R01 · FY2013 · NS · contact PI
Endocannabinoids in Neurodegenerative Diseases$315,000
R01 · FY2012 · NS · contact PI
MAGL Inhibition in Prevention and Treatment of Alzheimer's Disease$181,050
R21 · FY2012 · AG · contact PI
MAGL Inhibition in Prevention and Treatment of Alzheimer's Disease$150,875
R21 · FY2011 · AG · contact PI
MAGL Inhibition in Prevention and Treatment of Alzheimer's Disease$5,488
R21 · FY2011 · AG · contact PI
Endocannabinoids in COX-2-Mediated Synaptic Modification and Neurotoxicity$246,015
R01 · FY2010 · NS · contact PI
Endocannabinoids in COX-2-Mediated Synaptic Modification and Neurotoxicity$248,500
R01 · FY2009 · NS · contact PI
Endocannabinoids in COX-2-Mediated Synaptic Modification and Neurotoxicity$89,138
R01 · FY2009 · NS · contact PI
Astroglial Cells in Marijuana-Altered Synaptic Plasticity$71,000
R03 · FY2009 · DA · contact PI
Endocannabinoids in COX-2-Mediated Synaptic Modification and Neurotoxicity$248,500
R01 · FY2008 · NS · contact PI
Astroglial Cells in Marijuana-Altered Synaptic Plasticity$71,000
R03 · FY2008 · DA · contact PI
Endocannabinoids in COX-2-Mediated Synaptic Modification and Neurotoxicity$248,500
R01 · FY2007 · NS · contact PI
Pilot--Cyclooxygenases in neuronal synaptic plasticity$0
P20 · FY2002 · RR